🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Pembrolizumab

    Cardiff Oncology

    Anal Cancer Stage III A

    phase 1 small molecule active

    1 trial

  2. Pembrolizumab

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  3. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  4. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  5. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  6. Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 1 other active

    1 trial

  7. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  8. Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD

    Topiloric/Uriadec

    chronic liver disease

    phase 1 other active

    1 trial

  9. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  10. Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  11. Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  12. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  13. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi-aventis Healthcare Pty Ltd

    Colitis ulcerative

    phase 1 other active

    1 trial

  14. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  15. Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma

    Janssen-Cilag International N.V.

    Mild to Moderate Asthma

    phase 1 other active

    1 trial

  16. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  17. Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  18. Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  19. Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  20. Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

    Lacuna Pharma Pty Ltd

    Androgenetic alopecia

    phase 1 other active

    1 trial

  21. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  22. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  23. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

  24. Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

    The George Institute

    Diabetic retinopathy.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources